No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina | NY | Florida

Pylo Launches 4G Blood Pressure Monitor for Remote Patient Monitoring

Editor: What To Know

  • While operating like a traditional blood pressure monitor to patients, the 802-LTE quickly captures and transmits accurate blood pressure and heart rate measurements via encrypted 4G wireless sync to the intuitive Pylo application programming interface (API).
  • To ensure accessibility for patients of all technical skill levels, the 802-LTE comes fully preconfigured and requires users to press only a single button to use the device.
  • Designed specifically for RPM, it is a highly efficient and cost-effective device for physician practices, health systems, and employer wellness programs working to establish or grow remote patient monitoring programs.

February 3, 2021

Pylo Health proudly announced today the release of the Pylo 802-LTE, a cellular blood pressure monitor designed for patients undergoing remote physiological monitoring (RPM).

Pylo 802-LTE, from the creators of the Prevounce Platform, is the simplest, most secure way for patients to manage their blood pressure from home. Designed specifically for RPM, it is a highly efficient and cost-effective device for physician practices, health systems, and employer wellness programs working to establish or grow remote patient monitoring programs.

To ensure accessibility for patients of all technical skill levels, the 802-LTE comes fully preconfigured and requires users to press only a single button to use the device. While operating like a traditional blood pressure monitor to patients, the 802-LTE quickly captures and transmits accurate blood pressure and heart rate measurements via encrypted 4G wireless sync to the intuitive Pylo application programming interface (API). The Pylo API then automatically routes the blood pressure measurement data in real time to a user’s doctor, caregiver, family member, or other healthcare organization.

Development of the FDA-cleared and FCC-certified Pylo 802-LTE was prompted by the challenges associated with complex blood pressure monitoring devices, which include difficult setup requirements, inaccurate readings, and awkward user experience. Prevounce Health leadership witnessed these obstacles through the company’s work with provider and health plan clients on the Prevounce Remote Patient Monitoring software.

“Many patients who need to monitor their blood pressure are not tech savvy,” says Daniel Tashnek, founder of Pylo and Prevounce Health. “The configuration and additional steps required for setup and usage of Bluetooth or WiFi monitors represent significant hurdles for those who typically require hypertension management in the first place. The Pylo 802-LTE eliminates these barriers and, more importantly, helps bring the benefits of remote patient monitoring to our most vulnerable populations. Since the 802-LTE was designed specifically for clinical RPM, it has all the privacy and security features expected by patients and providers.”

Additional features include a comfortable cuff, large backlit screen, and an impressive battery life, all of which further help improve patient engagement and participation in remote patient monitoring programs.

“Research has shown that remote cardiac monitoring can greatly reduce patient blood pressure compared to typical care and self-monitoring alone,” Tashnek says. “With ongoing remote monitoring of hypertension via the Pylo 802-LTE, healthcare providers can make more timely recommendations that better support heart-healthy living for their patients.”

The proprietary Pylo Connect API makes it easy for organizations with RPM programs to manage patient readings, connected devices, product ordering, and more in any EMR or third-party care management system. Built with an emphasis on security and HIPAA compliance, the API’s features a fully serverless architecture using Amazon Web Services for scalability, a self-service developer portal, seamless data streaming via event-based webhooks, and a lightweight, RESTful interface.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Recent News

CV Societies Propel Plans Forward for a New Board of Cardiovascular Medicine

“The open comment period is the time for cardiovascular physicians, allies in other medical specialties, patients, and others to make their voices heard on why an independent CV Board is the best path for cardiologists to stay up-to-date on best practices and evidence-based care, ensuring patients receive the best possible care,” said Jeffrey Kuvin, MD, president of the proposed Board’s new Board of Directors. “The field of cardiovascular medicine has evolved dramatically over the past few decades; now is the right time to develop an independent cardiovascular Board.”

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."

Sedana Medical Completes Patient Recruitment for INSPiRE-ICU 1 Clinical Trial in the US

Peter Sackey further elaborated: "Once the 30-day follow-up of all patients is complete, we will enter into an intense phase of final monitoring, data cleaning and transfer to our statistician team for analysis. In parallel, the long-term outcomes at 3 and 6 months will be collected centrally by the Critical Illness, Brain Dysfunction, and Survivorship team at Vanderbilt Medical Center. With this parallel approach, we expect topline results in the autumn of this year and a swift regulatory submission in Q1, 2025".

Health / Lifestyle

Articles of Interest

Stay Connected

spot_img

About Medical Device News Magazine

About Medical Device News Magazine. A digital publication founded in 2008 located in the United States. The publication is one of the industry’s leading sources of medical device and biotech industry updates. Medical Device News Magazine is easily accessible 24/7/365 and is a fast 1, 2, 3 easy read! Our purpose is...

By using this website you agree to accept Medical Device News Magazine Privacy Policy